RecruitingPhase 1NCT07444619

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas


Sponsor

M.D. Anderson Cancer Center

Enrollment

18 participants

Start Date

Jun 9, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to build on the experience of the SAINT trial by evaluating the safety and efficacy of the addition of pazopanib to their published chemotherapy regimen.


Eligibility

Min Age: 1 YearMax Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ipilimumab, a drug called Nivolumab, and others for people with soft tissue sarcomas. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Year to 30 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPazopanib

Given by mouth

DRUGTrabectedin

Given by IV

DRUGIpilimumab

Given by IV

DRUGNivolumab

Given by IV


Locations(1)

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07444619


Related Trials